Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed National Cancer Institute (NCI)

RandomizedTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy with or without docetaxel in treating patients who have metastatic prostate cancer.

Timeline

Start: 2002-08
Primary completion: —
Completion: 2007-10

Publications

Results Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006 Feb 15;12(4):1260-9. doi: 10.1158/1078-0432.CCR-05-2059.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	—	Intravenous
Subject	rV-B7.1	Vaccine	—	Subcutaneous
Subject	rV-PSA	Vaccine	—	Subcutaneous
Subject	recombinant fowlpox-prostate specific antigen vaccine	Vaccine	—	Subcutaneous
Background	sargramostim	Protein / enzyme biologic	—	Subcutaneous

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications